Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide;Control metabólico y pérdida de peso en pacientes con obesidad y diabetes mellitus tipo 2 tratados con exenatida

Medicina Clinica

Volumn 139, Issue 13, 2012, Pages 572-578

  Pujante Alarcón, Pedro ^a   Hellín Gil, María Dolores ^a   Román, Luis Miguel ^b   Ferrer Gómez, Mercedes ^a   García Zafra, María Victoria ^a,b   Tébar Massó, Javier ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Exenatide; Obesity; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; AGED; ANTI-OBESITY AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC EMPTYING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; NAUSEA; OBESITY; PEPTIDES; SATIETY RESPONSE; TREATMENT OUTCOME; VENOMS; VOMITING; WEIGHT LOSS; YOUNG ADULT;

EID: 84868589778     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2011.10.025     Document Type: Article

References (27)

1. J. Salas-Salvado, M.A. Rubio, M. Barbany, and B. Moreno [SEEDO 2007 Consensus for the evaluation of overweight and obesity and the establishment of therapeutic intervention criteria] Med Clin (Barc) 128 2007 184 196
2. P. Gaede, P. Vedel, H.H. Parving, and O. Pedersen Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study Lancet 353 1999 617 622
3. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
4. M.J. Perley, and D.M. Kipnis Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects J Clin Invest 46 1967 1954 1962
5. M. Nauck, F. Stockmann, R. Ebert, and W. Creutzfeldt Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 29 1986 46 52
6. M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, and W. Creutzfeldt Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741 744
7. C. Guidone, M. Manco, E. Valera-Mora, A. Iaconelli, D. Gniuli, and A. Mari Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery Diabetes 55 2006 2025 2031
8. H. Linnebjerg, P.A. Kothare, Z. Skrivanek, A. de la Pena, M. Atkins, and C.S. Ernest Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes Diabet Med 23 2006 240 245
9. J.B. Buse, R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 27 2004 2628 2635
10. R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman, and A.D. Baron Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 2005 1092 1100
11. D.C. Klonoff, J.B. Buse, L.L. Nielsen, X. Guan, C.L. Bowlus, and J.H. Holcombe Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 24 2008 275 286
12. D.A. Stoffers, T.J. Kieffer, M.A. Hussain, D.J. Drucker, S. Bonner-Weir, and J.F. Habener Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas Diabetes 49 2000 741 748
13. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, and R. Sherwin Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
14. Summary of revisions for the 2010 Clinical Practice Recommendations. Diabetes Care 2010; 33 Suppl 1:S3.
15. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
16. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
17. J.A. Velasco, J. Cosin, J.M. Maroto, J. Muniz, J.A. Casasnovas, and I. Plaza [Guidelines of the Spanish Society of Cardiology for cardiovascular disease prevention and cardiac rehabilitation] Rev Esp Cardiol 53 2000 1095 1120
18. P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
19. P. De Pablos Velasco, J. Franch, J.R. Banegas Banegas, S. Fernandez Anaya, A. Sicras Mainar, and S. Diaz Cerezo [Cross-sectional epidemiological study of clinical profiles and glycemic control in diabetic patients in primary care in Spain (the EPIDIAP study)] Endocrinol Nutr 56 2009 233 240
20. C. Comi-Diaz, J.M. Miralles-Garcia, L. Cabrerizo, M. Perez, X. Masramon, and P. De Pablos-Velasco [Cardiovascular risk factor control in a population with longstanding diabetes attending endocrinology departments] Endocrinol Nutr 57 2010 472 478
21. M.M. Roca-Rodriguez, F. Carral-San Laureano, G. Baena-Nieto, and M. Aguilar-Diosdado [Evaluation of metabolic control targets in patients with type 2 diabetes mellitus] Endocrinol Nutr 57 2010 434 439
22. R. Bhushan, K.E. Elkind-Hirsch, M. Bhushan, W.J. Butler, K. Duncan, and O. Marrioneaux Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting Diabetes Technol Ther 11 2009 353 359
23. E.S. Horton, C. Silberman, K.L. Davis, and R. Berria Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database Diabetes Care 33 2010 1759 1765
24. U.A. Nayak, J. Govindan, V. Baskar, D. Kalupahana, and B.M. Singh Exenatide therapy in insulin-treated type 2 diabetes and obesity QJM 103 2010 687 694
25. J.B. Buse, D.J. Drucker, K.L. Taylor, T. Kim, B. Walsh, and H. Hu DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 33 2010 1255 1261
26. T.J. Moretto, D.R. Milton, T.D. Ridge, L.A. Macconell, T. Okerson, and A.M. Wolka Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 30 2008 1448 1460
27. D.J. Drucker, J.B. Buse, K. Taylor, D.M. Kendall, M. Trautmann, and D. Zhuang Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250